Cargando…

Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation

OBJECTIVE: Idiopathic orbital inflammation (IOI) is a group of orbital inflammatory diseases of unknown etiopathogenesis. We investigated whether patients with IOI have clinical heterogeneity based on the presence (typical group) or absence (atypical group) of a unique onset that periocular inflamma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubota, Toshinobu, Iwakoshi, Akari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171215/
https://www.ncbi.nlm.nih.gov/pubmed/36161858
http://dx.doi.org/10.1136/bmjophth-2022-001005
_version_ 1784721616065789952
author Kubota, Toshinobu
Iwakoshi, Akari
author_facet Kubota, Toshinobu
Iwakoshi, Akari
author_sort Kubota, Toshinobu
collection PubMed
description OBJECTIVE: Idiopathic orbital inflammation (IOI) is a group of orbital inflammatory diseases of unknown etiopathogenesis. We investigated whether patients with IOI have clinical heterogeneity based on the presence (typical group) or absence (atypical group) of a unique onset that periocular inflammatory symptoms emerge suddenly but progress slowly. METHODS AND ANALYSIS: This retrospective cohort study included 195 patients diagnosed with IOI. We analysed the clinical data of patients, including the outcomes of corticosteroid treatment, in two subgroups stratified on the basis of the presence (130 patients) or absence (65 patients) of the unique onset. RESULTS: Patients in the typical group were significantly younger at disease onset than those in the atypical group (median age; 52 vs 65 years, p=0.002); had more ocular adnexa-specific lesions, namely, dacryoadenitis, myositis, scleritis and optic perineuritis (78% vs 45%, p=0.00001); and had significantly fewer associations with immune-mediated inflammatory diseases (4% vs 15%, p=0.004). Among 30/119 patients (25%) who were steroid refractory in the typical group, a long period of time from symptom onset to initiation of treatment was a significant steroid-refractory risk factor (OR: 16.7), whereas, among the 18/40 patients (45%) who were steroid refractory in the atypical group, intraconal diffuse lesions were a significant steroid-refractory risk factor (OR: 8.8). CONCLUSION: This cohort study suggests clinical heterogeneity between the two subgroups of patients with IOI.
format Online
Article
Text
id pubmed-9171215
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91712152022-06-16 Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation Kubota, Toshinobu Iwakoshi, Akari BMJ Open Ophthalmol Orbit and Oculoplastics OBJECTIVE: Idiopathic orbital inflammation (IOI) is a group of orbital inflammatory diseases of unknown etiopathogenesis. We investigated whether patients with IOI have clinical heterogeneity based on the presence (typical group) or absence (atypical group) of a unique onset that periocular inflammatory symptoms emerge suddenly but progress slowly. METHODS AND ANALYSIS: This retrospective cohort study included 195 patients diagnosed with IOI. We analysed the clinical data of patients, including the outcomes of corticosteroid treatment, in two subgroups stratified on the basis of the presence (130 patients) or absence (65 patients) of the unique onset. RESULTS: Patients in the typical group were significantly younger at disease onset than those in the atypical group (median age; 52 vs 65 years, p=0.002); had more ocular adnexa-specific lesions, namely, dacryoadenitis, myositis, scleritis and optic perineuritis (78% vs 45%, p=0.00001); and had significantly fewer associations with immune-mediated inflammatory diseases (4% vs 15%, p=0.004). Among 30/119 patients (25%) who were steroid refractory in the typical group, a long period of time from symptom onset to initiation of treatment was a significant steroid-refractory risk factor (OR: 16.7), whereas, among the 18/40 patients (45%) who were steroid refractory in the atypical group, intraconal diffuse lesions were a significant steroid-refractory risk factor (OR: 8.8). CONCLUSION: This cohort study suggests clinical heterogeneity between the two subgroups of patients with IOI. BMJ Publishing Group 2022-06-05 /pmc/articles/PMC9171215/ /pubmed/36161858 http://dx.doi.org/10.1136/bmjophth-2022-001005 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Orbit and Oculoplastics
Kubota, Toshinobu
Iwakoshi, Akari
Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation
title Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation
title_full Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation
title_fullStr Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation
title_full_unstemmed Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation
title_short Clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation
title_sort clinical heterogeneity between two subgroups of patients with idiopathic orbital inflammation
topic Orbit and Oculoplastics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171215/
https://www.ncbi.nlm.nih.gov/pubmed/36161858
http://dx.doi.org/10.1136/bmjophth-2022-001005
work_keys_str_mv AT kubotatoshinobu clinicalheterogeneitybetweentwosubgroupsofpatientswithidiopathicorbitalinflammation
AT iwakoshiakari clinicalheterogeneitybetweentwosubgroupsofpatientswithidiopathicorbitalinflammation